JAK1 and cancer: Recent studies of triple-negative breast cancer (TNBC) samples have shown that inhibition of JAK1/2 by ruxolitinib sensitizes cancer cells to paclitaxel, both in-vitro and in-vivo (Lian et al. 2020; Han et al. 2021).